Plasma biomarker concentration (pg/ml) before (pre-treament) and after 28 days after sorafenib treatment.

<p>Plasma biomarker concentration (pg/ml) before (pre-treament) and after 28 days after sorafenib treatment.</p

Sorafenib reduces the vessel density in sarcoma lesions.

<p>Immunostaining of CD31-positive (brown) or CD31 and α-SMA-positive (brown and pink) tumor vessels before (A) and 28 days after (B) the initiation of sorafenib treatment. Sections were counterstained with hematoxylin. Note the reduced vessel density and cellular content in the sorafenib-treated lesion.</p

Adverse events after sorafenib treatment in advanced soft tissue sarcoma patients: number of episodes/number of affected patients (percentage).

<p>Adverse events after sorafenib treatment in advanced soft tissue sarcoma patients: number of episodes/number of affected patients (percentage).</p

Flow Diagram.

<p>Flow Diagram.</p

Clinical characteristics.

<p>Clinical characteristics.</p

Vascular Density.

<p>Vascular Density.</p

Kaplan-Meier Curves of Progression-Free Survival (PFS) and Overall Survival (OS) Distributions after Vandetanib with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients.

<p><b>A</b>, PFS distribution for all patients (n = 27). <b>B</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20). <b>C</b>, PFS distribution for all patients (n = 27). <b>D</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20).</p

Study CONSORT Flow Diagram.

<p>Study CONSORT Flow Diagram.</p

Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and 15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.

<p>Data are shown as medians and interquartile ranges (in square brackets) compared to baseline levels. <i>P</i>-values are from the exact paired Wilcoxon test, before and after adjustment for multiple comparisons over time using the method of Genovese at al. VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; PlGF, placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2, soluble VEGF receptor-2; SDF-1α, stromal cell-derived factor-1-alpha; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.</p

Waterfall Plot.

<p>Best response analysis after vandetanib with cetuximab and irinotecan limited to patients with confirmed KRAS wild-type metastatic colorectal cancer and at least 1 restaging imaging scan.</p